Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Get Rating) in a report published on Thursday morning. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of NASDAQ:ADXS opened at $0.99 on Thursday. Ayala Pharmaceuticals has a one year low of $0.65 and a one year high of $7.20.

About Ayala Pharmaceuticals

(Get Rating)

Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.